Robert Ticktin Biography and Net Worth

General Counsel & COO of PMV Pharmaceuticals

Prior to joining PMV Pharma, Mr. Ticktin was Associate General Counsel, Corporate, at Tesaro, Inc., a development and commercial oncology company (acquired by GSK), where he led corporate legal matters, including SEC reporting, business development and alliance management support. Prior to Tesaro, he was Senior Vice President and General Counsel at Epirus Biopharmaceuticals, a biosimilar company. Before his tenure at Epirus, Mr. Ticktin spent 10 years at Amgen Inc., where he held various leadership positions in the legal department. He began his legal career in New York City at global law firms, Simpson Thacher & Bartlett LLP and Latham & Watkins LLP. Mr. Ticktin received a B.A. in Economics from The Ohio State University and a J.D. from Fordham University School of Law.

What is Robert Ticktin's net worth?: The estimated net worth of Robert Ticktin is at least $143.60 thousand as of July 1st, 2025. Mr. Ticktin owns 98,695 shares of PMV Pharmaceuticals stock worth more than $143,601 as of September 18th. This net worth evaluation does not reflect any other assets that Mr. Ticktin may own. Learn More about Robert Ticktin's net worth.
How do I contact Robert Ticktin?: The corporate mailing address for Mr. Ticktin and other PMV Pharmaceuticals executives is 400 Alexander Park Drive, Suite 301, Princeton, NJ, 08540. PMV Pharmaceuticals can also be reached via phone at 609-642-6670 and via email at [email protected]. Learn More on Robert Ticktin's contact information.
Has Robert Ticktin been buying or selling shares of PMV Pharmaceuticals?: Robert Ticktin has not been actively trading shares of PMV Pharmaceuticals during the past quarter. Most recently, Robert Ticktin sold 23,151 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $1.06, for a transaction totalling $24,540.06. Following the completion of the sale, the chief operating officer now directly owns 98,695 shares of the company's stock, valued at $104,616.70. Learn More on Robert Ticktin's trading history.
Who are PMV Pharmaceuticals' active insiders?: PMV Pharmaceuticals' insider roster includes Leila Alland (Insider), Richard Heyman (Director), Deepika Jalota (Chief Development Officer), Winston Kung (CFO), Arnold Levine (Director), David Mack (CEO), Thilo Schroeder (Director), and Robert Ticktin (General Counsel & COO). Learn More on PMV Pharmaceuticals' active insiders.
Are insiders buying or selling shares of PMV Pharmaceuticals?: During the last twelve months, insiders at the sold shares 1 times. They sold a total of 1,000,000 shares worth more than $1,520,000.00. The most recent insider tranaction occured on October, 23rd when Major Shareholder Orbimed Advisors Llc sold 1,000,000 shares worth more than $1,520,000.00. Insiders at PMV Pharmaceuticals own 10.2% of the company. Learn More about insider trades at PMV Pharmaceuticals.
Information on this page was last updated on 10/23/2025.

Robert Ticktin Insider Trading History at PMV Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/1/2025	Sell	23,151	$1.06	$24,540.06	98,695

Robert Ticktin Buying and Selling Activity at PMV Pharmaceuticals

PMV Pharmaceuticals Company Overview

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Today's Range

Now: $1.49

$1.43

$1.52

50 Day Range

MA: $1.28

$1.07

$1.46

2 Week Range

Now: $1.49

$1.02

$1.88

Volume

344,681 shs

Average Volume

492,219 shs

Market Capitalization

$79.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37